RXRX (Recursion Pharmaceuticals) EPS (Basic): $-1.20 (TTM As of Mar. 2026)

What is Recursion Pharmaceuticals EPS (Basic)?

Recursion Pharmaceuticals RXRX +2.22% 77 EPS (Basic) is $-1.20 as of Mar. 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Recursion Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.20.

Recursion Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.20.

Recursion Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was $-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.20.

During the past 3 years, the average EPS without NRI Growth Rate was -1.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Recursion Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -1.90% per year. The lowest was -35.60% per year. And the median was -16.05% per year.

Recursion Pharmaceuticals (NAS:RXRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Recursion Pharmaceuticals EPS (Basic) Related Terms

Recursion Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals EPS (Basic) Chart

Recursion Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-1.49

-1.36

-1.58

-1.69

-1.44

Recursion Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.50	-0.41	-0.36	-0.21	-0.22

77GF Score

Recursion Pharmaceuticals Inc RXRX

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Recursion Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Recursion Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-644.759	-	0)	/	447.446
	=	-1.44

Recursion Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-117.504	-	0)	/	529.304
	=	-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.20

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-1.20 mean?

Recursion Pharmaceuticals (RXRX) has a EPS (Basic) of $-1.20 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Recursion Pharmaceuticals and its competitors.

Is Recursion Pharmaceuticals' EPS (Basic) too high?

Recursion Pharmaceuticals' current EPS (Basic) is $-1.20. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Recursion Pharmaceuticals' EPS (Basic) compare to RAPP and SRPT?

Recursion Pharmaceuticals' EPS (Basic) of $-1.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current EPS (Basic) is $-1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Recursion Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.16, compared to a current price of $3.25 — trading 21.9% below its estimated fair value. The current EPS (Basic) is $-1.20. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current EPS (Basic) is $-1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.25 is trading 21.9% below its estimated GF Value™ of $4.16. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

EPS (Basic): $-1.20
GF Value™: $4.16 vs. price of $3.25 (21.9% below fair value)
GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies RAPP SRPT ABCL STOK SION VRDN ADMA ZYME NTLA AUPH VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RXRX:Mexico

Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101

Website https://www.recursion.com

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

77GF Score

Get the complete analysis for RXRX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25

Price

$4.16

GF Value

View RXRX Analysis

See EPS (Basic) data for all stocks →